Herceptin

Herceptin
Fvasconcellos 02:36, 28 May 2007 (UTC) · Public domain · source
Drug name	Herceptin
Tradename	Herceptin
Routes of administration	Intravenous infusion
Legal status	Prescription-only
Atc prefix	L01
Atc suffix	FD01
Metabolism	Reticuloendothelial clearance
Elimination half-life	1–30 days (dose- and time-dependent)
Excretion	Catabolism to peptides and amino acids

Herceptin is a monoclonal antibody used to treat certain HER2-overexpressing cancers. It is primarily indicated for subsets of breast cancer and gastric cancer characterized by amplification or overexpression of the ERBB2 gene. Developed as a targeted biologic, it has altered clinical paradigms in oncology and influenced policy and research in precision medicine, oncology trials, and pharmaceutical regulation.

Medical uses

Herceptin is indicated for adjuvant and metastatic treatment of HER2-positive breast cancer and for HER2-overexpressing advanced gastric cancer and gastroesophageal junction adenocarcinoma. In early-stage disease it is combined with chemotherapy regimens such as those containing doxorubicin, cyclophosphamide, paclitaxel, or docetaxel to reduce recurrence risk. For metastatic disease it is used as monotherapy or in combination with agents like trastuzumab emtansine or platinum-based regimens depending on prior therapy and receptor status. Use requires confirmed HER2 status by immunohistochemistry or fluorescence in situ hybridization testing, often guided by recommendations from organizations such as the American Society of Clinical Oncology and the European Society for Medical Oncology.

Mechanism of action

Herceptin binds the extracellular domain of the human epidermal growth factor receptor 2 protein encoded by ERBB2 and inhibits downstream signaling cascades including the PI3K–AKT pathway and MAPK pathway. Binding leads to receptor downregulation, inhibition of dimerization with family members like EGFR, and induction of antibody-dependent cellular cytotoxicity mediated by natural killer cell recognition via FCGR3A. The blockade of HER2-driven proliferative and survival signals reduces tumor cell proliferation and can increase sensitivity to cytotoxic agents used in combination.

Administration and dosing

Herceptin is administered by intravenous infusion, generally in hospital or infusion-center settings, with dosing schedules that include an initial loading dose followed by maintenance infusions every one to three weeks depending on formulation and indication. Dosing adjustments are informed by body weight, prior exposure to HER2-targeted agents such as pertuzumab, and concurrent cardiotoxic therapies like anthracycline agents. Clinical management incorporates baseline and periodic assessment with echocardiography or multigated acquisition scan to monitor left ventricular ejection fraction per guidance from regulatory agencies including the Food and Drug Administration and the European Medicines Agency.

Side effects and safety

Common adverse effects include infusion-related reactions, fever, nausea, and myalgia, reported in trials led by cooperative groups such as the National Surgical Adjuvant Breast and Bowel Project and organizations including National Comprehensive Cancer Network that shape supportive care. A major safety concern is cardiotoxicity manifesting as reduced left ventricular ejection fraction and congestive heart failure, particularly when combined with doxorubicin or other anthracycline chemotherapy; this has prompted monitoring protocols recommended by bodies like the American Heart Association. Rare but serious events include severe hypersensitivity, pulmonary toxicity, and infusion-related anaphylaxis, managed in practice by teams at institutions such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.

Pharmacology and pharmacokinetics

As an IgG1 monoclonal antibody, Herceptin exhibits nonlinear pharmacokinetics with a half-life that increases with repeated dosing due to target-mediated drug disposition; observed terminal half-lives range broadly based on population studies. Distribution is primarily extracellular, and clearance occurs via proteolytic catabolism in the reticuloendothelial system; interactions with small-molecule agents are limited but pharmacodynamic interactions occur with agents affecting cardiac function. Population pharmacokinetic modeling used in clinical development employed data from multinational trials including those coordinated by Roche and cooperative oncology groups to define dosing regimens across diverse patient demographics.

Development and regulatory history

Herceptin was developed through collaborations between biotechnology firms and academic laboratories, emerging from research on receptor tyrosine kinases and the HER2 oncogene first characterized in molecular studies influenced by investigators at universities and institutes such as University of California laboratories and Dana-Farber Cancer Institute. Clinical development included pivotal randomized trials comparing adjuvant and metastatic regimens that influenced approval decisions by regulatory agencies including the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its approval marked a landmark in targeted therapy, leading to subsequent companion diagnostic development and influencing reimbursement debates involving health systems and payers like NHS England and insurers across jurisdictions. The drug's history intersects with policy decisions, patent litigation, and biosimilar development involving manufacturers in regions such as European Union markets and United States regulatory pathways.

Category:Monoclonal antibodies Category:Breast cancer treatment Category:Antineoplastic agents